JP2014517279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517279A5 JP2014517279A5 JP2014510475A JP2014510475A JP2014517279A5 JP 2014517279 A5 JP2014517279 A5 JP 2014517279A5 JP 2014510475 A JP2014510475 A JP 2014510475A JP 2014510475 A JP2014510475 A JP 2014510475A JP 2014517279 A5 JP2014517279 A5 JP 2014517279A5
- Authority
- JP
- Japan
- Prior art keywords
- mucosal healing
- individual
- markers
- combinations
- index
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035876 healing Effects 0.000 claims 31
- 238000000034 method Methods 0.000 claims 20
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 14
- 238000011269 treatment regimen Methods 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 239000003550 marker Substances 0.000 claims 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 108010008165 Etanercept Proteins 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000012896 Statistical algorithm Methods 0.000 claims 3
- 229960002964 adalimumab Drugs 0.000 claims 3
- 229960000403 etanercept Drugs 0.000 claims 3
- 229940048921 humira Drugs 0.000 claims 3
- 229960000598 infliximab Drugs 0.000 claims 3
- 229940116176 remicade Drugs 0.000 claims 3
- 102100038778 Amphiregulin Human genes 0.000 claims 2
- 101800001382 Betacellulin Proteins 0.000 claims 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims 2
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims 2
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 claims 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 2
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 claims 2
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims 2
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 claims 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 101001109792 Homo sapiens Pro-neuregulin-2, membrane-bound isoform Proteins 0.000 claims 2
- 101001109765 Homo sapiens Pro-neuregulin-3, membrane-bound isoform Proteins 0.000 claims 2
- 101001109767 Homo sapiens Pro-neuregulin-4, membrane-bound isoform Proteins 0.000 claims 2
- 101001056707 Homo sapiens Proepiregulin Proteins 0.000 claims 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 2
- 102000048238 Neuregulin-1 Human genes 0.000 claims 2
- 108090000556 Neuregulin-1 Proteins 0.000 claims 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 2
- 102100022668 Pro-neuregulin-2, membrane-bound isoform Human genes 0.000 claims 2
- 102100022659 Pro-neuregulin-3, membrane-bound isoform Human genes 0.000 claims 2
- 102100022658 Pro-neuregulin-4, membrane-bound isoform Human genes 0.000 claims 2
- 102100029837 Probetacellulin Human genes 0.000 claims 2
- 102100025498 Proepiregulin Human genes 0.000 claims 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 2
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 claims 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 2
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims 2
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 230000007246 mechanism Effects 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- 238000011903 nutritional therapy Methods 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000011285 therapeutic regimen Methods 0.000 claims 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- -1 IL-1β Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 229940090100 cimzia Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 229940073621 enbrel Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161484607P | 2011-05-10 | 2011-05-10 | |
| US61/484,607 | 2011-05-10 | ||
| US201161505026P | 2011-07-06 | 2011-07-06 | |
| US61/505,026 | 2011-07-06 | ||
| US201161553909P | 2011-10-31 | 2011-10-31 | |
| US61/553,909 | 2011-10-31 | ||
| US201161566509P | 2011-12-02 | 2011-12-02 | |
| US61/566,509 | 2011-12-02 | ||
| US201261636575P | 2012-04-20 | 2012-04-20 | |
| US61/636,575 | 2012-04-20 | ||
| PCT/US2012/037375 WO2012154987A1 (en) | 2011-05-10 | 2012-05-10 | Methods of disease activity profiling for personalized therapy management |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017225123A Division JP2018072349A (ja) | 2011-05-10 | 2017-11-22 | 個別治療管理のための疾患活動性プロファイリングの方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014517279A JP2014517279A (ja) | 2014-07-17 |
| JP2014517279A5 true JP2014517279A5 (enExample) | 2015-06-25 |
Family
ID=46147068
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510475A Pending JP2014517279A (ja) | 2011-05-10 | 2012-05-10 | 個別治療管理のための疾患活動性プロファイリングの方法 |
| JP2017225123A Ceased JP2018072349A (ja) | 2011-05-10 | 2017-11-22 | 個別治療管理のための疾患活動性プロファイリングの方法 |
| JP2020006298A Pending JP2020098213A (ja) | 2011-05-10 | 2020-01-17 | 個別治療管理のための疾患活動性プロファイリングの方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017225123A Ceased JP2018072349A (ja) | 2011-05-10 | 2017-11-22 | 個別治療管理のための疾患活動性プロファイリングの方法 |
| JP2020006298A Pending JP2020098213A (ja) | 2011-05-10 | 2020-01-17 | 個別治療管理のための疾患活動性プロファイリングの方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10086072B2 (enExample) |
| EP (1) | EP2707504A1 (enExample) |
| JP (3) | JP2014517279A (enExample) |
| KR (1) | KR20140032424A (enExample) |
| CN (2) | CN103649336A (enExample) |
| AU (1) | AU2012253422B2 (enExample) |
| BR (1) | BR112013028808A2 (enExample) |
| CA (1) | CA2839792A1 (enExample) |
| IL (1) | IL229120B (enExample) |
| MX (2) | MX362132B (enExample) |
| RU (1) | RU2013154566A (enExample) |
| SG (1) | SG194710A1 (enExample) |
| WO (1) | WO2012154987A1 (enExample) |
| ZA (1) | ZA201309258B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| AU2012253422B2 (en) | 2011-05-10 | 2015-08-13 | Société des Produits Nestlé S.A. | Methods of disease activity profiling for personalized therapy management |
| EP2946214A1 (en) * | 2013-01-21 | 2015-11-25 | AbbVie Inc. | Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease |
| ES2751391T3 (es) | 2013-03-21 | 2020-03-31 | Univ Michigan Regents | Procedimientos de tratamiento de trastornos metabólicos |
| EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
| WO2015110989A1 (en) * | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
| US10846371B2 (en) * | 2014-04-10 | 2020-11-24 | Yissum Research Development Company of the Hebrew University of Jerusalm Ltd. | Methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder |
| WO2015166461A1 (en) | 2014-05-01 | 2015-11-05 | Nestec S.A. | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels |
| WO2015169966A2 (en) * | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| WO2015175926A1 (en) * | 2014-05-15 | 2015-11-19 | Children's Medical Center Corporation | Systems and methods for identifying neurobiological biomarkers using eeg |
| MX2017004742A (es) | 2014-10-20 | 2017-07-20 | Nestec Sa | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. |
| WO2016088068A1 (en) | 2014-12-02 | 2016-06-09 | Nestec S.A. | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
| EP3227683B1 (en) | 2014-12-05 | 2019-04-24 | Nestec S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
| US20180224464A1 (en) * | 2015-06-09 | 2018-08-09 | Osaka University | Method of predicting and determining therapeutic effect on rheumatoid arthritis due to biological formulation |
| WO2017027709A1 (en) | 2015-08-11 | 2017-02-16 | Cognoa, Inc. | Methods and apparatus to determine developmental progress with artificial intelligence and user input |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| JP2019514939A (ja) * | 2016-04-26 | 2019-06-06 | クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． | 標的組織における自然免疫応答の治療的誘発 |
| CN109476698B (zh) | 2016-05-20 | 2023-10-17 | 西达-赛奈医疗中心 | 基于基因的炎性肠病诊断 |
| GB201611738D0 (en) | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
| EP3529379B1 (en) | 2016-10-24 | 2022-05-18 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | System and method for implementing meal selection based on vitals, genotype, and phenotype |
| WO2018085937A1 (en) * | 2016-11-14 | 2018-05-17 | Qu Biologics Inc. | Managing site specific ibd immunotherapies |
| CN110192252A (zh) | 2016-11-14 | 2019-08-30 | 科格诺亚公司 | 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置 |
| US20220254461A1 (en) * | 2017-02-09 | 2022-08-11 | Cognoa, Inc. | Machine learning algorithms for data analysis and classification |
| EP3580700A4 (en) * | 2017-02-09 | 2020-11-18 | Cognoa, Inc. | PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE |
| CN111094984A (zh) | 2017-05-31 | 2020-05-01 | 普罗米修斯生物科学公司 | 克罗恩氏病患者的粘膜愈合评估方法 |
| KR20200069333A (ko) | 2017-10-10 | 2020-06-16 | 프로메테우스 바이오사이언시즈, 인크. | 베돌리주맙 치료를 모니터링하는 방법 |
| US11270800B1 (en) * | 2017-11-09 | 2022-03-08 | Aptima, Inc. | Specialized health care system for selecting treatment paths |
| KR102424222B1 (ko) * | 2017-11-13 | 2022-07-21 | 더 멀티플 마이얼로머 리서치 파운데이션, 인크. | 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스 |
| WO2019178546A1 (en) | 2018-03-16 | 2019-09-19 | Scipher Medicine Corporation | Methods and systems for predicting response to anti-tnf therapies |
| JP2020028278A (ja) * | 2018-08-24 | 2020-02-27 | 国立大学法人九州大学 | 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法 |
| MX2021011493A (es) | 2019-03-22 | 2022-01-04 | Cognoa Inc | Métodos y dispositivos de terapia digital personalizados. |
| CN109998488B (zh) * | 2019-04-13 | 2022-08-02 | 中国医学科学院北京协和医院 | 克罗恩病和肠道溃疡型淋巴瘤的鉴别模型及构建方法 |
| AU2020275413A1 (en) | 2019-05-14 | 2021-12-23 | Cedars-Sinai Medical Center | TL1A patient selection methods, systems, and devices |
| CA3145237A1 (en) * | 2019-06-27 | 2020-12-30 | Scipher Medicine Corporation | Developing classifiers for stratifying patients |
| WO2021097074A1 (en) * | 2019-11-13 | 2021-05-20 | New York University | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury |
| US20230352174A1 (en) * | 2020-12-29 | 2023-11-02 | Kpn Innovations, Llc. | Systems and methods for generating a parasitic infection program |
| US20240395384A1 (en) * | 2021-09-30 | 2024-11-28 | Prometheus Laboratories Inc. | Patient centric precision model for anti-tnf therapy |
| WO2023064437A1 (en) * | 2021-10-15 | 2023-04-20 | The Trustees Of Indiana University | Methods for detecting fracture-related infection (fri) |
| CN114859060B (zh) * | 2022-05-06 | 2025-01-28 | 广州市胸科医院 | 一种细胞因子组及其应用 |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
| US11887720B1 (en) * | 2023-01-23 | 2024-01-30 | Kpn Innovations, Llc | Apparatus and method for using a feedback loop to optimize meals |
| US12362058B2 (en) | 2023-01-23 | 2025-07-15 | Kpn Innovations, Llc. | Apparatus and method for using a feedback loop to optimize meals |
| WO2025250715A1 (en) * | 2024-05-30 | 2025-12-04 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and related aspects for rapid cytokine detection for inflammatory disease diagnosis |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1262493A1 (en) | 1992-10-29 | 2002-12-04 | Bayer Corporation | Diagnostic assay for latent matrix metalloproteinase no. 9 |
| DK0615129T3 (da) | 1993-03-10 | 2000-08-07 | Cedars Sinai Medical Center | Fremgangsmåder til selektiv påvisning af perinukleært anti-neutrophilt cytoplasmatisk antistof fra ulcerativ colitis eller |
| US5830675A (en) | 1993-03-10 | 1998-11-03 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis |
| US20020025553A1 (en) | 1996-01-04 | 2002-02-28 | Ying-Fei Wei | Transforming growth factor alpha HIII |
| US6074835A (en) | 1996-04-12 | 2000-06-13 | Regents Of The Univ. Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1 |
| US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| US6319899B1 (en) | 1997-09-17 | 2001-11-20 | The Nemours Foundation | Method and composition for the treatment of inflammatory bowel disease |
| US6218129B1 (en) | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
| RU2141332C1 (ru) | 1998-06-24 | 1999-11-20 | Научно-исследовательский институт фармакологии Томского научного центра РАМН | Противоязвенное средство и способ его получения |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| US6309643B1 (en) | 1999-04-30 | 2001-10-30 | The Regents Of The University Of California | IBD-associated microbial antigens and methods of using same |
| FR2802536B1 (fr) | 1999-11-23 | 2003-06-13 | Chru Lille | Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections |
| FR2806739B1 (fr) | 2000-03-27 | 2005-02-18 | Fond Jean Dausset Ceph | Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| US7138237B1 (en) | 2000-05-19 | 2006-11-21 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen |
| AU1169702A (en) | 2000-10-13 | 2002-04-22 | Childrens Medical Center | Non-invasive enzyme screen for tissue remodelling-associated conditions |
| WO2002036773A2 (en) | 2000-10-30 | 2002-05-10 | Regents Of The University Of Michigan | Nod2 nucleic acids and proteins |
| AU4341502A (en) | 2000-10-30 | 2002-06-11 | Univ Michigan | Nod2 nucleic acids and proteins |
| EP1340078B1 (en) | 2000-11-14 | 2009-05-27 | Techlab, Inc. | Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrin as a marker |
| US20050154536A1 (en) | 2001-08-30 | 2005-07-14 | The University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Two-part drug discovery system |
| EP1432984A4 (en) | 2001-08-30 | 2009-01-14 | Univ Pittsburgh | ALGORITHM FOR ASSESSING THE RESULTS OF INFLAMMATION FOR INJURY OR INFECTION |
| AU2002365279B2 (en) | 2001-12-17 | 2009-08-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| US20040053263A1 (en) | 2002-08-30 | 2004-03-18 | Abreu Maria T. | Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease |
| CA2502976C (en) | 2002-10-25 | 2012-05-22 | Techlab, Inc. | Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel |
| US20040197304A1 (en) | 2003-04-01 | 2004-10-07 | The Procter & Gamble Company And Alimentary Health, Ltd. | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
| US7662569B2 (en) | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
| WO2005009339A2 (en) | 2003-05-30 | 2005-02-03 | Pathway Diagnostics Corporation, Inc. (a Delaware Corporation) | Inflammatory bowel diseases |
| ATE490275T1 (de) | 2003-06-23 | 2010-12-15 | Genetics Inst Llc | Antikörper gegen interleukin-22 und verwendungen dafür |
| EP1687447A4 (en) | 2003-11-03 | 2008-04-02 | Univ Duke | METHOD FOR IDENTIFYING INDIVIDUALS IN THE HAZARD OF PERIOPERATIVE BLOODING, A KIDNEY PROBLEM OR A STROKE |
| MX350383B (es) | 2004-01-09 | 2017-09-04 | Pfizer | Anticuerpos contra madcam. |
| FI119572B (fi) | 2004-03-05 | 2008-12-31 | Biohit Oyj | Menetelmä vatsan limakalvon tilan ennustamiseksi |
| US20060019410A1 (en) | 2004-07-21 | 2006-01-26 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
| EP1810198A1 (en) | 2004-09-09 | 2007-07-25 | Université de Liège | Identification and use of biomarkers for the diagnosis and the prognosis of inflammatory diseases. |
| AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
| JP2009513645A (ja) | 2005-10-26 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | ＩＬ−１β化合物の新規使用 |
| JP2009541338A (ja) | 2006-06-19 | 2009-11-26 | ワイス | Ｉｌ−２２およびｉｌ−１７の調節方法 |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| RU2442171C2 (ru) | 2006-09-21 | 2012-02-10 | Промитьюс Лабораториз Инк. | Чипы на основе антител для определения множественных трансдукторов сигналов в редких циркулирующих клетках |
| US8165819B2 (en) | 2006-10-10 | 2012-04-24 | The University of Pittsburgh—Of the Commonwealth System of Higher Education | Modeling wound healing |
| WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
| US20100255513A1 (en) | 2007-03-30 | 2010-10-07 | Denson Lee A | Serological markers of inflammatory bowel disease phenotype and disease progression |
| GB2447865A (en) | 2007-03-30 | 2008-10-01 | Ethicon Inc | Diagnostic markers of wound infection |
| WO2008147869A2 (en) * | 2007-05-22 | 2008-12-04 | Centocor, Inc. | Markers and methods for assessing and treating crohn's disease and related disorders |
| AU2008276251B2 (en) | 2007-07-13 | 2014-04-24 | Nestec S.A. | Drug selection for lung cancer therapy using antibody-based arrays |
| EP2602623B1 (en) | 2008-02-25 | 2015-09-16 | Nestec S.A. | Mehtod for the detection of intracellular truncated receptors |
| JP5550633B2 (ja) | 2008-03-26 | 2014-07-16 | セラノス， インコーポレイテッド | 臨床転帰を評価するための方法およびシステム |
| US20110059445A1 (en) * | 2008-03-28 | 2011-03-10 | Paul Rutgeerts | Mucosal gene signatures |
| CA2734604A1 (en) * | 2008-08-25 | 2010-04-22 | Centocor Ortho Biotech Inc. | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders |
| AU2009285644B2 (en) * | 2008-08-29 | 2015-08-20 | Janssen Biotech, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel |
| BRPI1013560A2 (pt) | 2009-04-14 | 2018-06-19 | Prometheus Laboratories Inc | métodos para auxiliar no prognóstico de doença instestinal inflamatória, e para predizer a probabilidade que um indivíduo diagnosticado com doença intestinal inflamatória responderá a um agente terapêutico de doença intestinal inflamatória |
| US20120046197A1 (en) | 2009-05-01 | 2012-02-23 | Meso Scale Technologies, Llc | Biomarkers of therapeutic responsiveness |
| EP2430443B1 (en) | 2009-05-14 | 2018-06-27 | Pierian Holdings, Inc. | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| AU2010266028B2 (en) | 2009-06-25 | 2015-04-30 | Société des Produits Nestlé S.A. | Methods for diagnosing irritable bowel syndrome |
| EP2454598B1 (en) | 2009-07-15 | 2017-03-22 | DiaTech Holdings, Inc. | Drug selection for gastric cancer therapy using antibody-based arrays |
| EA026401B1 (ru) | 2009-09-02 | 2017-04-28 | Новартис Аг | Иммуногенные композиции, содержащие модуляторы активности tlr |
| AU2010306593B2 (en) * | 2009-10-15 | 2015-09-10 | Crescendo Bioscience, Inc. | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| CA2777934A1 (en) | 2009-10-20 | 2011-04-28 | Prometheus Laboratories Inc. | Proximity-mediated assays for detecting oncogenic fusion proteins |
| NZ599456A (en) | 2009-10-26 | 2014-06-27 | Nestec Sa | Assays for the detection of anti-tnf drugs and autoantibodies |
| AU2010324735A1 (en) | 2009-11-25 | 2012-07-12 | Nestec S.A. | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| EP2539470B1 (en) | 2010-02-24 | 2017-02-22 | The Board of Trustees of The Leland Stanford Junior University | Methods for autoimmune disease diagnosis, prognosis, and treatment |
| MX2012014096A (es) | 2010-06-04 | 2013-04-19 | Nestec Sa | Métodos para mejorar el diagnóstico de enfermedad intestinal inflamatoria. |
| US20140148350A1 (en) | 2010-08-18 | 2014-05-29 | David Spetzler | Circulating biomarkers for disease |
| SG10201510086VA (en) | 2010-12-23 | 2016-01-28 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| EP2908132B8 (en) | 2011-03-02 | 2019-06-12 | Nestec S.A. | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures |
| AU2012253422B2 (en) | 2011-05-10 | 2015-08-13 | Société des Produits Nestlé S.A. | Methods of disease activity profiling for personalized therapy management |
| KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
| MX352274B (es) | 2011-10-21 | 2017-11-16 | Nestec Sa | Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal. |
| SG11201405273YA (en) | 2012-02-29 | 2014-09-26 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
| ES2638971T3 (es) | 2012-10-05 | 2017-10-24 | Nestec S.A. | Métodos para predecir y monitorizar la cicatrización de la mucosa |
| US20140113306A1 (en) | 2012-10-17 | 2014-04-24 | Rutgers, The State University Of New Jersey | Diagnostic and screening methods for inflammation |
| CN113156139A (zh) | 2013-01-03 | 2021-07-23 | 梅索磅秤技术有限公司 | 测定实验对象组 |
| US20140236166A1 (en) | 2013-02-15 | 2014-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers for distinguishing benign, pre-malignant, and malignant pancreatic cysts |
| WO2015110989A1 (en) | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
| JP6904905B2 (ja) | 2014-12-24 | 2021-07-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗α４β７インテグリン抗体による治療の結果の予測 |
| EP3247343A1 (en) | 2015-01-23 | 2017-11-29 | Nestec S.A. | Nutritional composition useful in the treatment of ibd patients |
| MX2017010336A (es) | 2015-02-26 | 2017-12-20 | Genentech Inc | Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn. |
| CN111094984A (zh) | 2017-05-31 | 2020-05-01 | 普罗米修斯生物科学公司 | 克罗恩氏病患者的粘膜愈合评估方法 |
| WO2020117795A1 (en) | 2018-12-04 | 2020-06-11 | Prometheus Biosciences, Inc. | Assessment and monitoring of mucosal healing in children and adults with crohn's disease |
-
2012
- 2012-05-10 AU AU2012253422A patent/AU2012253422B2/en not_active Ceased
- 2012-05-10 WO PCT/US2012/037375 patent/WO2012154987A1/en not_active Ceased
- 2012-05-10 KR KR1020137032638A patent/KR20140032424A/ko not_active Ceased
- 2012-05-10 SG SG2013080585A patent/SG194710A1/en unknown
- 2012-05-10 CA CA2839792A patent/CA2839792A1/en active Pending
- 2012-05-10 MX MX2013013096A patent/MX362132B/es active IP Right Grant
- 2012-05-10 BR BR112013028808A patent/BR112013028808A2/pt not_active Application Discontinuation
- 2012-05-10 EP EP12722621.5A patent/EP2707504A1/en not_active Ceased
- 2012-05-10 RU RU2013154566/15A patent/RU2013154566A/ru unknown
- 2012-05-10 CN CN201280034138.2A patent/CN103649336A/zh active Pending
- 2012-05-10 CN CN201910821596.4A patent/CN110544517A/zh active Pending
- 2012-05-10 JP JP2014510475A patent/JP2014517279A/ja active Pending
-
2013
- 2013-10-28 IL IL229120A patent/IL229120B/en active IP Right Grant
- 2013-11-05 US US14/072,746 patent/US10086072B2/en active Active
- 2013-11-08 MX MX2018008324A patent/MX2018008324A/es unknown
- 2013-12-09 ZA ZA2013/09258A patent/ZA201309258B/en unknown
-
2017
- 2017-11-22 JP JP2017225123A patent/JP2018072349A/ja not_active Ceased
-
2018
- 2018-08-24 US US16/112,242 patent/US11160863B2/en active Active
-
2020
- 2020-01-17 JP JP2020006298A patent/JP2020098213A/ja active Pending
-
2021
- 2021-09-24 US US17/484,786 patent/US12485171B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014517279A5 (enExample) | ||
| RU2013154566A (ru) | Способы анализа профиля активности болезни с целью проведения индивидуального лечения | |
| Johnson et al. | Pulmonary hypertension: a contemporary review | |
| Agache et al. | Advances and highlights in asthma in 2021 | |
| Moschen et al. | IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting | |
| Smolen et al. | Patients with rheumatoid arthritis in clinical care | |
| Maronese et al. | Biologics for hidradenitis suppurativa: evolution of the treatment paradigm | |
| RU2016147569A (ru) | Способы лечения воспалительного заболевания кишечника | |
| Dunne et al. | Effect of post-exercise hydrotherapy water temperature on subsequent exhaustive running performance in normothermic conditions | |
| Hartley et al. | Severe asthma: novel advances in the pathogenesis and therapy | |
| JP2015532425A5 (enExample) | ||
| Calabresi et al. | One year in review 2018: psoriatic arthritis | |
| Tillisch et al. | 589 modulation of the brain-gut axis after 4-week intervention with a probiotic fermented dairy product | |
| Linares et al. | Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn’s disease | |
| Thomas et al. | Diagnosis and treatment options for T2-low asthma | |
| Shen et al. | Advancing personalised precision treatment for Still's disease based on molecular characteristics and disease progression | |
| Quintana et al. | A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population | |
| JP2010526303A5 (enExample) | ||
| Felipez et al. | North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease | |
| Atzeni et al. | The therapeutic journey of biologic agents: There will be an end? | |
| Glickman et al. | Large‐Scale Blood Proteomic Analysis Across Different Inflammatory Skin Conditions Reveals Extensive Immune Dysregulation With Distinct Biomarker Profiles | |
| Tanaka et al. | Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept | |
| Diver et al. | Beyond T2-inflammation: What Does the Future Hold for Severe Asthma? | |
| van de Putte | ARD launches an advanced online publication programme | |
| Tassone et al. | impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib. |